Silverberg Bernstein Capital Management LLC Has $2.23 Million Position in Lantheus Holdings, Inc. $LNTH

Key Points

• Silverberg Bernstein Capital Management LLC increased its position in Lantheus Holdings, Inc. by 28.6% in Q2, holding 27,179 shares valued at $2.23 million.
• Lantheus reported Q2 earnings of $1.57 EPS, missing expectations, with revenues of $378.05 million, a 4.1% decline from the previous year.
• Recent insider trading saw Farallon Partners sell 3.365 million shares for approximately $188.9 million, significantly decreasing their stake by 49.18%.

Silverberg Bernstein Capital Management LLC grew its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 28.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,179 shares of the medical equipment provider's stock after acquiring an additional 6,050 shares during the period. Lantheus accounts for approximately 1.5% of Silverberg Bernstein Capital Management LLC's investment portfolio, making the stock its 18th biggest holding. Silverberg Bernstein Capital Management LLC's holdings in Lantheus were worth $2,225,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Signaturefd LLC grew its holdings in Lantheus by 36.5% during the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 116 shares during the period. Quarry LP grew its stake in shares of Lantheus by 2,350.0% in the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider's stock valued at $48,000 after buying an additional 470 shares during the period. Hughes Financial Services LLC acquired a new stake in shares of Lantheus in the 1st quarter valued at about $81,000. UMB Bank n.a. grew its stake in shares of Lantheus by 68.2% in the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after buying an additional 381 shares during the period. Finally, Blue Trust Inc. grew its stake in shares of Lantheus by 117.7% in the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock valued at $114,000 after buying an additional 633 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Price Performance

LNTH stock opened at $51.74 on Tuesday. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $118.21. The business has a 50-day simple moving average of $63.43 and a two-hundred day simple moving average of $80.91. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The company has a market capitalization of $3.52 billion, a P/E ratio of 13.76 and a beta of 0.15.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The firm had revenue of $378.05 million for the quarter, compared to the consensus estimate of $389.69 million. During the same period in the prior year, the business earned $1.80 EPS. Lantheus's quarterly revenue was down 4.1% compared to the same quarter last year. Research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the company. TD Cowen reduced their target price on Lantheus from $95.00 to $80.00 and set a "buy" rating for the company in a research note on Monday. William Blair restated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Truist Financial set a $63.00 target price on Lantheus and gave the company a "hold" rating in a research note on Monday, August 11th. JMP Securities cut their price target on Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. Finally, B. Riley cut their price target on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $89.67.

Insider Activity at Lantheus

In other Lantheus news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. This trade represents a 49.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,812,000 shares of company stock worth $382,427,380. Insiders own 2.00% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.